Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385995 | 1.00 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1HRH3CHRNA7TP53BP1 | |
| SCHEMBL3383954 | 0.90 | L3MBTL1 (0.49) | L3MBTL3L3MBTL1HRH3TP53BP1ALDH1A1 | |
| SCHEMBL3385812 | 0.89 | HRH3 (0.48) | L3MBTL3L3MBTL1HRH3CHRNA7MGLL | |
| SCHEMBL3389792 | 0.88 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1HRH3TP53BP1MGLL | |
| SCHEMBL3388530 | 0.87 | HRH3 (0.45) | L3MBTL3L3MBTL1HRH3CHRNA7HPGD | |
| SCHEMBL3386037 | 0.84 | HRH3 (0.47) | HRH3CHRNA7 | |
| SCHEMBL3390885 | 0.84 | HRH3 (0.47) | HRH3CHRNA7 | |
| SCHEMBL3390331 | 0.83 | L3MBTL1 (0.55) | L3MBTL3L3MBTL1TP53BP1ALDH1A1MGLL | |
| SCHEMBL3388049 | 0.81 | HRH3 (0.43) | L3MBTL3L3MBTL1HRH3CHRNA7CNR2 | |
| SCHEMBL3387184 | 0.81 | HRH3 (0.44) | HRH3CHRNA7MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | claimed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | claimed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | claimed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | claimed |
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | L3MBTL3 4279/4885L3MBTL1 4407/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.